Pharmaceutical composition, methods for treating and uses thereof
AssigneeBoehringer Ingelheim International GmbH
InventorsPeter EICKELMANN, Michael Mark, Leo John Seman, Leo Thomas, Uli Christian Broedl, Rolf Grempler
Life of this patent
Estimating the term…
Abstract
The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
Claims23
1-20. (canceled)
A method for improving glycemic control and/or for reducing fasting plasma glucose and/or glycosylated hemoglobin HbA1c comprising administering to a patient in need thereof a pharmaceutical composition comprising 5 to 25 mg of the SGLT2 inhibitor 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, wherein said SGLT-2 inhibitor is administered to the patient orally once daily.
A method for improving glycemic control comprising administering to a patient with type 2 diabetes mellitus a pharmaceutical composition comprising 10 mg of the SGLT2 inhibitor 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, wherein said SGLT-2 inhibitor is administered to the patient orally once daily as an adjunct to diet and exercise.
A method for improving glycemic control comprising administering to a patient with type 2 diabetes mellitus a pharmaceutical composition comprising 25 mg of the SGLT2 inhibitor 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, wherein said SGLT-2 inhibitor is administered to the patient orally once daily as an adjunct to diet and exercise.
Dependencies are inferred from the claim text.